PR94340

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022, /PRNewswire=KYODO JBN/ --

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a

South African headquartered multinational pharmaceutical company announced

today their partnership to  launch Trelstar(R) (Triptorelin) in South Africa

for the treatment of locally advanced and metastatic hormone dependent prostate

cancer.  (Trelstar(R), a synthetic analogue of GnRH (Gonadotropin Releasing

Hormone) developed by Debiopharm, will be marketed by Aspen in South Africa.

In 2020, nearly 14,000 South African men were newly diagnosed with prostate

cancer1 with an average of 5 men dying from the disease every day.2 In fact, 1

in every 23 South African men will develop prostate cancer in their lifetime.2

Trelstar works by reducing testosterone levels, a hormone essential to prostate

cancer growth. Deprivation of testosterone stops the growth of hormone

dependent prostate cancer, alleviating pain and improving the quality of life

of patients.

We're really enthusiastic to enter into this new alliance with Aspen, a

well-established and trusted pharmaceutical partner for the commercialization

of Trelstar(R) in South Africa and recognize the therapeutic benefits that

Trelstar(R) could bring to prostate cancer patients in this region. Fabrice

Paradies, Senior Director, Business Development & Global Commercial Alliances,

Debiopharm.

Aspen Pharmacare is excited to be able to deliver a world class oncology

product in the treatment of prostate cancer and we are privileged to partner

with Debiopharm to commercialize Trelstar(R) within the South African market.

We are confident that this product will add significant benefit to the

treatment of prostate cancer. Neel Andhee-Shah, Head: New Product Development,

Aspen Pharmacare.

About Trelstar(R) (Triptorelin)

Trelstar(R) (Triptorelin) is an agonist analogue of the natural

gonadotropin-releasing hormone (GnRH). Debiopharm has developed three

sustained-release formulations (1, 3 and 6 months) of Triptorelin Pamoate.

First registered in France in 1986, Triptorelin is currently marketed in more

than 80 countries by Debiopharm's selected partners and is market leader in

many territories worldwide.

About Aspen

Headquartered in Durban, South Africa, Aspen is a partner of choice as it is a

global specialty and branded multinational pharmaceutical company with a

presence in both emerging and developed markets. Aspen improves the health of

patients in more than 150 countries through its high quality and affordable

medicines. Active at every stage of the value chain, Aspen is uniquely

diversified by geography, product and manufacturing capability. The

Group's key business segments are Manufacturing and Commercial Pharmaceuticals

comprising Regional Brands and Sterile Focus Brands. For more information,

please visit https://www.aspenpharma.com/.

Debiopharm's commitment to patients

Debiopharm develops innovative therapies that target high unmet medical needs

in oncology and infectious diseases. Bridging the gap between disruptive

discovery products and international patient reach, we identify high-potential

compounds and technologies for in-licensing, clinically demonstrate their

safety and efficacy and then select large pharmaceutical commercialization

partners to maximize patient access globally.

Visit us www.debiopharm.com/  

Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Debiopharm Contact

Dawn Bonine – Head of Communications

dawn.bonine@debiopharm.com  

Tel: +41 (0)21 321 01 11

References

1. Globocan 2020;

https://gco.iarc.fr/today/data/factsheets/populations/913-southern-africa-fact-sheets.pdf

2.  https://mensfoundation.co.za/mens-health/prostate-cancer/

SOURCE: Debiopharm International SA